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ABSTRACT 
Background: Obesity in childhood and adolescents is a major concern in Sweden, as in many parts of the world. 
Already during the pediatric years is obesity associated with several metabolic complications, which often persists into 
adulthood. An important metabolic concern is the disturbance of the glucose-insulin homeostasis. One early sign is 
impaired fasting glycaemia (IFG) which is considered a prediabetic stage as IFG is associated with markedly increased 
risk for development of type 2 diabetes mellitus (T2DM) in adults. IFG refers to elevated, but not yet diabetic, glucose 
levels in the fasting state. At present, two different cut-off values for IFG are used in parallel; the American Diabetes 
Association (ADA) suggest 5.6 mmol/L and the World Health Organization (WHO) promotes 6.1 mmol/L as the 
cut-off for IFG. In adults, IFG has been associated with increased risk for cardiovascular disease, cancer, and 
premature also in the absence of the development of T2DM.  
The prevalence of IFG in the obese pediatric population has been reported with vast differences across different 
countries and populations. Further, the long-term consequences of IFG in the obese pediatric population are not clear. 
However, obesity as well as obesity-induced dysglycemia, may affect several brain functions important for schooling. 
The aim of this thesis is to investigate the prevalence, risk groups, and consequences of IFG in obese children and 
adolescents. 
Method: All studies included in this thesis contains data from the Swedish Childhood Obesity Register – BORIS (Barn 
Obesitas Register I Sverige). BORIS is a national quality register for obesity treatment in childhood and adolescence 
and was initiated in 2005. In addition, data from Germany and Poland regarding children and adolescents who have 
been undergoing obesity treatment are included.  Study I and II are cross-sectional observational studies and Study III 
and IV are prospective cohort studies, which in addition to BORIS data using data from several national registries. 
Results: The total prevalence of IFG among obese children in the German cohort according to the ADA was 5.7% 
and according to the WHO it was 1.1%. In Sweden, the corresponding prevalence was 17.1% and 3.9%, respectively. 
IFG risk was associated with increasing age, male sex and degree of obesity. Further, Swedish obese young children 
had higher glucose levels than Polish obese young children. 
The use of T2DM medication retrieved from the national prescribed drug registry was used as a proxy for the diagnosis 
of T2DM. The pediatric obese population in Sweden, based on the BORIS cohort, had a 24 times increased use of 
T2DM medications in early adulthood in relation to a population-based comparison group, regardless of gender and 
ethnicity. While the WHO-defined IFG predicted future use of T2DM medication in early adulthood with an adjusted 
hazard ratio of 3.84 compared with those who had fasting glucose levels <5.6mmol/L. A fasting glucose level of 5.6-
6.0 mmol/L, i.e. the IFG glucose interval added by ADA, did not increase the use of T2DM medication in young 
adults more than pediatric obesity itself. Female gender and more severe degree of obesity increased the risk for future 
T2DM medication.  
In the obese cohort, 55.4% completed ≥12 years in school, compared with 76.2% in the comparison group. IFG did 
not correlate significantly with school completion; 50.8% for those with IFG according to ADA and 48.4% for those 
with IFG according to WHO completed school compared with 55.8% for non-IFG. When analyzing glucose as a 
continuous variable, a non-significant tendency on school completion could be seen (adjusted p=0.06). 
Conclusion: IFG is highly prevalent among obese children in Sweden compared with Poland and Germany. There 
are no known explanations for the large regional differences in both IFG prevalence and fasting glucose levels. IFG 
according to WHO, but not the additional interval added by ADA (5.6-6.0 mmol/L) can be considered as a prediabetic 
stage in the obese pediatric population. Thus, these studies indicate that risk markers identified in adults can not directly 
be transferred to children. Obesity in childhood and adolescence was associated with low educational level in early 
adulthood but IFG did not statistically significantly increase the risk for low education in obese individuals. 
  
SVENSK POPULÄRVETENSKAPLIG SAMMANFATTNING 
(SWEDISH LAY SUMMARY) 
Fetma hos barn och ungdomar hör till våra största hot mot folkhälsan. Hos vuxna ökar fetma risken för en rad 
sjukdomar, bland annat hjärtkärlsjukdom och typ 2 diabetes (T2D). Hos barn med fetma är dessa följdsjukdomar 
sällsynta, men förstadier till dem finns. Ett sådant tidigt tecken är förhöjt fasteblodsocker, eller engelskans impaired 
fasting glycemia (IFG), som hos vuxna är ett förstadium till T2D. I dagsläget finns det två olika gränser för IFG: en 
lägre gräns satt av American Diabetes Association (ADA) med blodsocker tagna efter en natts fasta på ≥5,6 mmol/L 
och en högre gräns som är satt av Världshälsoorganisationen (WHO), ≥6,1 mmol/L. Vuxna individer med IFG har 
ökad risk för hjärtkärlsjukdom, cancer och förtidig död, även om diabetes inte utvecklas. Både fetma i sig, T2D och 
förhöjda fasteblodsocker kan påverka hjärnans mentala processer, såsom inlärning och minne. Huruvida IFG hos barn 
och ungdomar som lider av fetma medför samma risker som IFG gör bland vuxna är inte känt.  
Den här avhandlingens syften är att utvärdera  
1. förekomsten av IFG hos barn och ungdomar som lider av fetma  
2. om det går att identifiera vilka barn som har högst risk att få IFG  
3. huruvida de barn och ungdomar som har IFG utvecklar diabetes i vuxen ålder 
4. om IFG minskar chansen att avsluta gymnasieutbildning 
Metod 
Alla studier i den här avhandlingen innehåller material från BarnObesitasRegistret I Sverige (BORIS). BORIS är ett 
kvalitetsregister som inkluderar barn och ungdomar som får fetmabehandling på barnläkarmottagning eller barnklinik. 
Utöver det registret kommer data även från ett motsvarande nationellt barnfetmabehandlingsregister i Tyskland och 
ett lokalt behandlingsregister i Polen. För patienterna i BORIS har vi också samlat in data från svenska nationella 
register avseende utbildning, läkemedelsanvändning och sjukdomsdiagnoser. För de longitudinella studierna av 
patienterna i BORIS finns en kontrollgrupp som Statistiska centralbyrån matchat på kön, födelseår och bostadsområde. 
All data i avhandlingen är därmed registerbaserad. 
Resultat 
I den tyska gruppen var den totala förekomsten av IFG enligt ADA 5,7% och enligt WHO 1,1%. I Sverige var den 
respektive förekomsten påfallande mycket högre, 17,1% respektive 3,9%, trots att vi justerat för ålder och grad av 
fetma, vilket annars skulle kunna påverka resultaten. Vidare hade de svenska barnen med fetma högre blodsockernivåer 
än polska barn. Risken för IFG ökade med stigande ålder, grad av fetma och om man var pojke. 
Vi använde diabetesläkemedel som markör för T2D eftersom diabetesdiagnoser är mer osäkert registrerade än 
läkemedelsanvändning. Detta beror på att T2D ofta sköts i primärvården, vars diagnoser inte rapporteras till nationella 
register. Barn med fetma i Sverige hade en markant ökad risk att få diabetesläkemedel i tidig vuxen ålder i jämförelse 
med en populationsbaserad kontrollgrupp, oberoende av kön och etnicitet. IFG definierat av WHO förutspådde 
framtida användning av T2D-medicinering hos vuxna. Däremot, det utökade sockerintervallet som ADA definierat, 
ökade inte användningen av T2D-medicinering hos unga vuxna mer än barnfetma i sig. Dessutom hade kvinnor högre 
risk för framtida T2D-medicinering trots att IFG var vanligare bland pojkar. Allvarlig fetma i barndomen ökade också 
risken för T2D-medicinering hos unga vuxna.  
Av de barn som led av fetma avslutade 55,4% gymnasiet, jämfört med 76,2% i kontrollgruppen. Av dem med lätt 
förhöjda blodsockervärden (IFG ADA) avslutade 50,8% gymnasiet, och 48,4% av de med mycket förhöjda 
blodsockervärden (IFG WHO), jämfört med 55,8% för de med normalt fasteblodsocker, men skillnaderna var inte 
statistiskt säkerställda.  
Slutsats 
Den här avhandlingen visar att barn och ungdomar med fetma i Sverige har en hög risk att ha förhöjda fasteblodsocker, 
både jämfört med normalviktiga men även jämfört med barn och ungdomar med fetma i såväl Tyskland som Polen. 
Vidare visar den att lätt förhöjda fasteblodsocker (IFG ADA), som hos vuxna är ett förstadium till diabetes, inte 
förutspår diabetes mer än fetma i sig hos barn och ungdomar. Angående samband mellan höga fasteblodsocker och 
sannolikheten att avsluta gymnasiet fanns det en trend, men den var inte statistiskt säkerställt. Fetma i sig påverkade 
däremot allvarligt sannolikheten att ta studenten. 
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1 PERSONAL NOTES 
 
Ever since I was a child I have been eager to understand how things work within the human body. 
Consequently, the nutritionist education was a natural choice for me and created a path into the 
field of science. I am grateful that I have been given the opportunity to conduct my PhD-studies 
at Karolinska Institutet. 
This thesis provides epidemiological research within the field of disturbed glucose metabolism as 
a consequence of obesity in childhood and adolescence. Even though we are getting closer to be 
able to identify individuals in the obese pediatric population who display a higher risk for obesity 
related co-morbidities, there are still more research needed to be able to make a fair risk prediction. 
Unfortunately, it is evident that children and adolescents suffering from obesity not only fight the 
battle against health risks, but also a battle in their daily living life. The stigmatization and prejudice 
that obesity is associated with, should not primarily be a battle for obese, but for everybody in 
society and especially for staff who meet and work with obese individuals. 
The years of my PhD studies have been the most eventful time in my life. Thanks to participation 
in international congresses, I have got the opportunity to experience different cultures and seen 
many places I would not have done otherwise. I am also thankful for international collaborations 
which have resulted in two articles, which is included in this thesis. Even though this thesis is based 
on epidemiological research, I have a great interest in the cellular and molecular world, a topic I 
hope one day will have the chance to explore further. 
As for now, I am wrapping up my PhD studies, but I feel that I am far from done with research. 
I am confident in that life will offer more academic adventures and that I will keep on developing 
as a researcher. This prospect makes me really excited.  
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2 BACKGROUND 
2.1 OBESITY IN CHILDHOOD AND ADOLESCENCE 
2.1.1 Prevalence 
The prevalence of overweight and obesity in the pediatric population increased drastically from 
the 1980s in many European countries. The rise was leveling off in Sweden and some years ago, 
the prevalence of overweight in 10-year-olds was about 20%, including approximately 3-5% obese 
subjects.1 Overweight and obesity are more prevalent in southern Europe. The prevalence of 
overweight has been reported to be more than 30% in Spain, Italy, and Greece, whereas a 
prevalence of 15-20% has been reported in Germany, Poland, and Sweden.2 Obesity prevalence is 
higher in adolescents than in younger children, but it is also prevalent in children under 10 years 
of age. It has been reported to be 2.2% in Sweden and 4.7% in Germany.3 Data from studies of 
four-year-olds4 and from studies of cohorts with limited representativity5 may indicate that the 
prevalence of obesity in young Swedish children reported in international reviews is 
underestimated. Recent and systematically collected data for children and adolescents over 10 years 
of age are scarce and therefore, the development of obesity prevalence remains uncertain at the 
moment. The prevalence of obesity is lower in Europe than in many other areas of the world, i.e., 
the United States and Near/Middle East.6,7  
Rapid changes in the prevalence of childhood obesity in recent decades within a relatively stable 
population indicate that genetic factors are not the primary cause. Therefore, changes in the nature 
of the environment towards a more obesogenic society are the most likely cause for the rise in 
prevalence.8 Genetic or epigenetic, i.e. DNA-methylation and histone modification, differences 
predispose some individuals to be more susceptible for the obesogenic environment.9 Important 
factors for childhood obesity prevalence include: 1) societal factors, such as the marketing of 
energy-dense foods on television around the clock and an increase in traffic hazards for walkers 
and cyclists; 2) socioeconomic factors, such as income inequality; 3) physical inactivity, such as 
screen time, less participation in sports and increased motorized transportation, and 4) dietary 
habits, such as more widespread food purchasing opportunities, larger portion size, junk food 
consumption and sugar-sweetened beverages.6,10,11 However, other factors, such as viral infections 
may also contribute to the development.12  
2.1.2 Some Comorbidities Linked to Early Obesity 
Obesity related comorbidities or abnormalities are already evident in the pediatric population. 
Even if not all subjects in the pediatric obese population suffer from obesity-related sequelae, early 
disturbances should be taken seriously. Childhood obesity can adversely affect almost every organ 
system and serious consequences often become present, including hypertension, dyslipidemia, 
insulin resistance, non-alcoholic fatty liver disease (NAFLD), and psychological complications.  
2.1.2.1 Metabolic Consequences 
Pediatric obesity is associated with several metabolic complications during the pediatric years, as 
well as complications that persist into adulthood. Insulin resistance and increased levels of 
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circulating insulin are early signs of obesity that can be observed already in youth.13-16 Dyslipidemia 
may occur as a result of pediatric obesity. Convincing evidence suggests that obesity-related 
dyslipidemia tracks from early life into adulthood.17,18  
2.1.2.2 Cardiovascular Consequences  
High blood pressure has been shown to track from adolescence into adulthood.16 Hypertensive 
adults with concomitant prediabetes have been shown to have a more rapid progression to Type 
2 diabetes (T2DM) than prediabetic subjects without hypertension.19 Non-occurring nocturnal 
blood pressure dipping (non-dipping) is common among severely obese adolescents, and has been 
shown to be negatively associated with measures of insulin metabolism regardless of the degree of 
obesity or daytime blood pressure in obese, non-diabetic adolescents without diagnosed 
hypertension.20  
2.1.2.3 The Metabolic Syndrome 
The metabolic syndrome includes a cluster of metabolic, cardiovascular and auxological 
abnormalities involving high BMI or waist circumference, dysglycemia, elevated blood pressure, 
and dyslipidemia. There are no universal definitions of the metabolic syndrome in childhood, 
hence different suggestions are present.21-23 Children and adolescents with the metabolic syndrome 
have an increased risk of developing metabolic abnormalities24 and T2DM25,26 as adults. However, 
the metabolic syndrome is not a better predictor than high childhood BMI itself.26 
2.1.2.4 Liver Consequences  
NAFLD of different degrees of severity has become more prevalent in the pediatric population 
due to obesity27 and is now the most common liver abnormality in children.28 Up to 38% of obese 
children have been shown to have NAFLD28, but it is often asymptomatic in children. However, 
almost all children with NAFLD are insulin resistant to some degree.29 
2.1.2.5 Systemic Subclinical Inflammation 
Obesity, and especially visceral obesity, leads to increased production of pro-inflammatory 
cytokines, i.e. C-reactive protein, interleukin 6, and tumor necrosis factor alpha. This is also 
observed in the obese pediatric population.30,31 Systemic subclinical inflammation is believed to be 
a crucial contributing factor to most other obesity-related physical comorbidities, i.e. macro and 
micro-vascular dysfunction, and the development of diabetes.32,33 
2.1.2.6 Psychological and Social Aspects 
Obesity in the pediatric population has pronounced consequences on the psychological and social 
domains. Stigmatization from peers, parents, and teachers is well-documented.34,35 Studies of self-
esteem are inconclusive. Older children seem to be more prone to lower self-esteem compared 
with peers of normal weight, but associations are often weak.6 
The association between obesity and depression is complex. Obese adolescents who seek 
treatment for their obesity display more symptoms of depression than subjects without obesity.36 
Some have found adolescent obesity to be associated with symptoms of depression37,38; some have 
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found modest associations39, while still others have not detected such associations in children and 
adolescents.40 It is also important to note that depression during childhood and adolescence is 
positively associated with BMI in adulthood; hence, reverse causality may be an explanation.40,41 
Severely obese children and adolescents have been shown to have lower health-related quality of 
life (QOL) than their healthy peers, and similar QOL as those diagnosed with cancer.42 Adults who 
suffered from childhood obesity have lower marital rates and lower income.43,44  
The long-term social consequences of childhood obesity, such as lower income and lower marriage 
frequency, have been established for more than 20 years.43,45 The potential relationship between 
obesity and school performance has also been addressed frequently, but the association is still 
unclear. Being obese in childhood and adolescence has been associated with poorer school 
performance and academic achievement in both school and population-based studies.43,45-48 
However, the conclusions are uncertain due to the fact that many studies have been cross-sectional, 
have used self-reported data for education, weight and height, or are based on a limited number 
of obese subjects. In addition, other studies have not been able to confirm any association between 
academic achievement and obesity49,50 or, as in one study, in females, but not in males.43  
In contrast to the physiological complications of obesity, the psychological and social aspects of 
obesity are highly linked to culture, where some cultures do not view excess weight as a negative 
attribute.6 
2.1.2.7 Reversibility of Comorbidities 
Weight reduction improves several of the abovementioned risks in young subjects with obesity. 
Reducing the degree of obesity in childhood and adolescence improves the lipid profile and insulin 
sensitivity.51-53 Individuals who are obese in childhood and become non-obese in adulthood have 
the same risk for T2DM, hypertension, adverse lipid profile, and intima media thickness as subjects 
who were never obese.54  
2.2 THE PHYSIOLOGY OF GLUCOSE HOMEOSTASIS 
In healthy subjects, blood glucose is firmly regulated by a complex interplay between neurological 
and endocrine factors. Most of these factors increase blood sugar and only one hormone, insulin, 
lowers blood sugar. This proves how important it is from an evolutional perspective to avoid 
hypoglycemia (see below), whereas hyperglycemia has only recently become a threat to human 
health. The major hormones directly involved in the homeostasis of blood glucose are insulin, 
glucagon, cortisol, growth hormone (GH), and the catecholamines adrenaline and 
noradrenaline.55,56 A schematic illustration of some of the major mechanisms of importance for 
blood glucose homeostasis is presented in Figure 1. 
The effects of these hormones depend primarily on two factors: the amount released from the 
producing organ and the sensitivity at the target organ. This is of primary importance for insulin, 
as this is the only blood glucose lowering hormone. Insulin resistance is a reduced capacity by the 
body to handle a glucose load despite normal insulin release.56 
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2.2.1 The Pancreas 
The Islets of Langerhans in the pancreas contain α-cells which produce glucagon, and β-cells which 
produce insulin. A basal plasma level of inulin is sustained by the pancreas and additionally secreted 
after ingesting carbohydrates. The postprandial release of insulin promotes glucose, amino acids, 
and fat uptake by the liver, muscles, and adipose tissue. Blood glucose levels are low when fasting, 
and under stress glucagon is released from the a-cells. Hence, insulin lowers the circulating glucose 
level, and glucagon maintains normal glucose levels or raises circulating glucose levels. Amylin is 
secreted from the β-cells in parallel with insulin and acts to decrease food intake, suppress glucagon 
release, and delay gastric emptying.55,56  
 
2.2.2 The Liver 
Insulin is not directly required for glucose uptake in the liver, as glucose is released or taken up in 
the liver depending on the concentration gradient via glucose transporter number two (GLUT 2). 
However, insulin stimulates phosphorylation of glucose and thereby increases the net uptake of 
glucose.57 Insulin decreases utilization of glycogen and promotes formation of glycogen. 
Furthermore, insulin inhibits gluconeogenesis, promotes the storage of fat, inhibits β-oxidation of 
fats, and stimulates protein synthesis.55  
Glucagon generally antagonizes the effects of insulin in the liver, where it promotes glycogen 
breakdown, gluconeogenesis and inhibits glycolysis. Additionally, glucagon promotes esterification 
of free fatty acids (FFA), which can either be stored or exported as VLDL particles. Alternatively, 
the liver can partly oxidize fatty acids and form ketone bodies, which can in turn be used as energy 
substrate in some tissues.55  
 
2.2.3 Muscle Tissue 
In the muscles, insulin increases GLUT 4 translocation to the cell membrane and thereby glucose 
uptake. Insulin promotes glycogen synthesis, glycolysis, and protein synthesis in muscles.55 Low 
basal glucose uptake is mediated via GLUT 1.58 Physical activity, independently of insulin, also 
activates glucose uptake via GLUT 4 translocation in the muscles.59 
 
2.2.4 Adipose Tissue 
In adipose tissue, insulin increases GLUT 4 translocation to the cell surface and thereby glucose 
uptake, promotes glycolysis to form glycerol-phosphate, and promotes conversion of pyruvate to 
FFAs and lactate. Further, insulin promotes formation of triglycerides.55 In adipose tissue, GLUT 
1 transporters are responsible for basal glucose uptake. Basal uptake is low in adults but probably 
higher in infants and young children.60  
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2.2.5 The Gastrointestinal Tract 
Incretins are a group of hormones that are released from the gastrointestinal tract in response to 
food intake. At present, the two major incretins are glucose-dependent insulinotropic polypeptide 
(GIP) and glucagone-like peptide-1 (GLP-1). Both of these stimulate decreased blood glucose 
levels by enhancing insulin release and decreasing glucagon release from the pancreas. Extrahepatic 
effects involve reduced systemically inflammation and increased thermogenesis.61 Targeting 
incretins is an emerging field within treatment for T2DM.62,63   
2.2.6 Fasting and Hypoglycemia 
Low blood glucose is acutely dangerous for any mammal. Therefore, the body has more 
mechanisms than the release of glucagon for raising blood glucose and switching energy sources. 
The body will respond with stress, and catecholamines, GH and glucocorticoids are released.56,64-66 
Catecholamines acutely increase lipolysis and FFA oxidation, which reduces glucose utilization and 
releases glycerol for gluconeogenesis.67 GH slowly stimulates the release and oxidation of FFAs, 
which leads to decreased glucose utilization and protein oxidation, and preservation of glycogen 
stores.66 Cortisol increases gluconeogenesis and protein breakdown, which provides substrate for 
gluconeogenesis.67 
While fasting, similar mechanisms are involved to maintain normal blood sugar levels. The initial 
response involves a reduction in insulin levels and increased glucagon levels. At last, the stress 
response involving the release of catecholamines and glucocorticoids occurs.67 GH in the fasting 
state also exerts mechanisms to maintain glucose concentrations.66 As a result, normal blood sugar 
can be maintained over days of fasting, contrary to popular belief.68  
It is noteworthy that the body has several metabolic responses to hypoglycemic levels, but only 
one metabolic response to hyperglycemia (Figure 1).64-66 
 
Figure 1. Schematic illustration of some of the major acute mechanisms of importance for blood glucose 
homeostasis. *Muscle and fat tissue can indirectly raise blood glucose by providing the liver substrate for glucose 
formation, and energy to reduce the glucose utilization. 
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2.2.7 Puberty and Pregnancy 
In metabolically healthy young people, insulin sensitivity decreases before and during puberty, and 
is lowest in Tanner stage 3, returning to almost prepubertal levels in Tanner stage 5 (end of 
puberty). Pubertal insulin insensitivity is believed to be primarily mediated by GH.69-72 
Pregnancy is normally attended by progressive insulin resistance that begins near mid-pregnancy 
and progresses until delivery. Pregnancy-induced insulin resistance results from the insulin-
desensitizing effects of hormones produced by the placenta, combined with increased maternal 
adiposity. The degree of insulin resistance might be as high as in individuals with T2DM.73 
Normally, insulin secretion increases to compensate for pregnancy-induced insulin resistance. 
However, if the insulin-producing β-cells are not able to compensate for the insulin resistance, 
gestational diabetes (GDM) with elevated glucose concentrations may occur.73 The risk of 
developing GDM is higher if the mother is already obese and insulin-resistant before pregnancy. 
Most cases of GDM resolve after delivery. However, these women have a documented reduced 
insulin secretory capacity and thus a substantially higher risk of developing T2DM later in life.73,74 
 
2.3 ALTERED GLUCOSE HOMEOSTASIS 
Metabolic perturbation may occur in obese subjects, leading to dysregulation of the glucose-insulin 
homeostasis. Many factors mentioned above may contribute to disturbances in glucose 
metabolism and insulin resistance, such as disturbed liver function, inflammation and physical 
inactivity. The final endpoint – if the genetic predisposition negatively affects the capacity to 
increase insulin secretion – is T2DM, but before that, changes in the homeostasis can be observed. 
Early signs, such as elevated glucose levels and impaired insulin sensitivity and beta-cell function, 
can be observed over a long and fairly stable period. But during the 2-4 years preceding a diabetes 
diagnosis, a steep deterioration of insulin sensitivity and fasting glucose levels can be observed.75 
In children with obesity, altered glucose metabolism is an early comorbidity marker.13 
 
2.4 PREDIABETES 
Prior to the onset of T2DM, a period of moderate hyperglycemia is often present, which is referred 
to as prediabetes. This can be observed in the fasting and/or in the postprandial stage. Even 
though prediabetes is a high-risk state for developing diabetes, many people with prediabetes do 
not progress to diabetes, which is why some prefer to use a different term, such as intermediate 
hyperglycemia.76,77 However, prediabetes is the most frequently used term. 
  
  9 
2.4.1 Definitions 
2.4.1.1 IFG 
Impaired fasting glucose or glycaemia (IFG) refers to elevated but not yet diabetic glucose levels 
in the fasting state. Two different cut-off values for IFG are currently used in parallel, which 
perhaps causes some confusion: the American Diabetes Association suggests 5.6 mmol/L76 and 
the World Health Organization promotes 6.1 mmol/L77 as the cut-off for IFG. The origin of these 
two definitions is discussed below. Testing whether IFG is present is fairly uncomplicated. All that 
is required to determine the fasting glucose level is a drop of blood in the morning before breakfast 
and an automatic glucometer, which is easy to use by everybody. 
2.4.1.2 IGT  
Impaired glucose tolerance (IGT) is defined by elevated postprandial glucose levels, which indicate 
an impairment in the body’s capacity to handle carbohydrates in a meal. IGT is evaluated via an 
oral glucose tolerance test (OGTT). The range for IGT is a 2h glucose level after an OGTT of 
7.8-11.0 mmol/L.76,77  
2.4.1.3 HbA1c 
HbA1c refers to glycated hemoglobin, which mirrors the overall blood glucose levels two-to-three 
months prior to testing. In recent years, HbA1c has emerged as a marker of prediabetes. 
Prospective studies show that subjects with HbA1c in the high range have a subsequent 5-year 
incidence of diabetes ranging from 12 to 25%.78-80 However, HbA1c has not been a successful 
identifier of dysglycemia, i.e. IFG and IGT, in children suffering from obesity.81-83 
2.4.2 The History of Prediabetes 
One of the earliest references to prediabetes was in 1965 by the WHO, Figure 2. At that time, 
prediabetes was not a state itself that could be identified, but a “term that can be used 
retrospectively when reviewing a case”. Hence, prediabetes could not be identified until the 
diagnosis of diabetes was made. WHO also stated that “it [prediabetes] should be used in research 
rather than in clinical settings” leaving it undiagnosed for the benefit of the patient, even though 
already in 1965, WHO concluded that “it is well-known that in the pre-diabetic stage, increased 
levels of insulin //… // may be found in the blood” and “some vascular changes may be 
present”.84  
  Figure 2. The 1965 definition of prediabetes from the World Health Organization. 
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In 1997, the ADA Expert Committee introduced the category of Impaired Fasting Glucose (IFG) 
to describe the zone between the upper limit of normal fasting plasma glucose and the lower limit 
of diabetic fasting plasma glucose. At that time, IFG was defined as 6.1-7.0 mmol/L. This was 
believed to correspond with the zone between the upper limit of a normal 2h plasma glucose and 
the lower limit of the diabetic 2h plasma glucose described as IGT. The cut-off of 6.1 mmol/L 
was adopted by WHO in 1999.77 In 2003, the ADA Expert Committee decided to reduce the cut-
off point for defining IFG from 6.1 mmol/L to 5.6 mmol/L. This was motivated by the fact that 
the prevalence of IFG should be similar to the prevalence of IGT. However, the reduced IFG cut-
off point has been questioned.85 
2.4.3 Prevalence of IFG in Childhood and Adolescence 
The prevalence of IFG in the obese pediatric population has been reported with vast differences 
across different countries and populations.86-91 However, many studies have been based on samples 
that are too small to be representative of entire populations. It is therefore unclear whether these 
variations in prevalence represent a true variation in the prevalence across different geographic 
areas. 
European studies have reported prevalence from 0-2% in Italy87,92 to 16% in the Netherlands (both 
using the ADA criteria).88,90,93 American studies have reported higher prevalence, ranging from 2-
9% (WHO criteria) and 15-47% (ADA criteria).86,91,94 Other countries, including India, China and 
Mexico, have reported a few percent with IFG in the obese pediatric population,89,95,96 whereas in 
Taiwan, 28% of obese adolescents have IFGADA.
97 Several challenges arise when attempting to 
compare these prevalence numbers, because different definitions of obesity have been used and 
different methods were used to recruit the sample populations, including both population-based 
samples and obesity clinic samples. It is thus unclear whether the variations in prevalence across 
different geographic areas are accurate.  
2.4.4 Who Will Develop Prediabetes as an Adult? 
Pediatric risk factors for developing IFG and T2DM have been reported to be BMI, TG, HDL 
cholesterol, IFG, and family history of T2DM.98,99  
Regarding parental factors, the longitudinal Cardiovascular Risk in Young Finns Study could 
identify maternal BMI as an important predictor of T2DM in the offspring.100 Furthermore, 
elevated fasting insulin concentrations in children aged 3-6 years are independently associated with 
an elevated risk of T2DM in adulthood. This relationship was not present in adolescents.101 
Other factors that have been shown to affect the risk of developing prediabetes and T2DM include 
exposure to certain antibiotic groups102 and persistent organic pollutants.103 In epidemiological 
studies, consumption of dairy products has been shown to be protective against T2DM.104 
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2.4.5 Pathophysiology of Prediabetes 
Plasma glucose in the fasting state is affected by several factors (Figure 3). The pathophysiology of 
IFG and IGT differ. Both stages represent insulin resistance, but at different locations in the body, 
and intermediate hyperglycemia, but on different occasions.  
IFG is associated with reduced hepatorenal insulin sensitivity, causing higher hepatic endogenous 
glucose production (EGP), combined with insufficient basal insulin secretion, resulting in elevated 
fasting glucose levels.105-108 Contrary, IGT is associated with peripheral insulin resistance, primary 
in the skeletal muscles.109 Furthermore, first phase insulin secretion has been shown to be impaired 
in subjects with both IFG and IGT. Second phase insulin secretion and peripheral insulin 
resistance in skeletal muscles seems to be normal in subjects with IFG but impaired in subjects 
with IGT.105,106,108,110 However, some physiological differences have been observed across different 
populations, indicating that the pathogenesis of IFG may differ in different ethnic groups.106 
Because IFG and IGT are distinct metabolic abnormalities, subjects with combined IFG and IGT 
have a more severe progression towards T2DM.19,111,112  
 
2.4.6 Prediabetes and Related Comorbidities in Obese Adolescents 
Prediabetes in obese children and adolescents has been associated with several cardiovascular 
changes. Young individuals with prediabetes have been shown to have increased arterial thickness 
and stiffness113, increased intima media thickness114 and elevated systolic blood pressure.113 
Furthermore, adolescents with prediabetes have been shown to have an atherogenic lipid profile.115 
Taken together, early in life, prediabetic obese youth display an adverse physiological profile that 
is most likely mediated by their dysglycemia.116 
2.4.7 Prediabetes, Comorbidities, and Risks in Adults 
Prediabetes is not only a risk factor for future diabetes, but also for other non-communicable 
diseases and for all-cause mortality. Even though IFG and IGT are often used together, they have 
separate pathophysiology and etiology and may have different associations with clinical events and 
mortality.108 
Fasting glucose
Physical 
activity
Stress
Diet
Genetics Medication
Infection
Metabolic 
regulation
Puberty
Figure 3. Fasting glucose levels are affected by several factors, including those that can and 
cannot be influenced by lifestyle changes. 
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2.4.7.1 Micro and Macrovascular Disease 
Prediabetes might be associated with an increased risk of retinopathy, neuropathy, early forms of 
nephropathy and chronic kidney disease.117 Prediabetes is also linked with increased risk of 
manifestations of vascular disease.118 However, the epidemiological relationship between 
prediabetes and macrovascular disease can be confounded by the clustering of vascular risk factors 
in individuals, since glucose levels in the prediabetic range are correlated with many risk factors, 
including general and central obesity, blood pressure, and dyslipidemia.118  
2.4.7.2 Cancer 
A meta-analysis published in 2014 using data from 16 prospective studies including more than 
890,000 subjects investigated the association between prediabetes and cancer development. They 
found that prediabetes was associated with an increased risk of cancer overall, Risk ratio (RR) 1.15 
95% [CI 1.06-1.23].119 Highly represented types of cancer included stomach/colorectal, liver, and 
endometrial cancer. Oddly, the authors found a higher RR for IFGADA than IFGWHO
119, suggesting 
that there are no dose-responses to the observed relationship. 
2.4.7.3 Cardiovascular Disease 
Higher glucose levels in the non-diabetic range increase the risk for (Cardiovascular disease) CVD. 
For post challenge glucose levels, a linear relationship with CVD is observed. However, for fasting 
plasma glucose, a light threshold appears around 5.6 mmol/L. The relationship is more 
pronounced in women than in men.120 
2.4.7.4 Mortality 
Already in the year 2000, data from the Hoorn Study showed that subjects with IFGWHO have 
increased risk for premature all-cause mortality.121 A later study of patients with coronary heart 
disease showed that prediabetes significantly increases the risk for premature mortality.122 A recent 
meta-analysis using data from 26 prospective studies investigated the association between 
prediabetes and the risk for premature all-cause mortality.123 They found that IFG according to 
WHO and IGT increase the risk for premature all-cause mortality and cardiovascular mortality, 
with a relative risk of about 1.15. However, IFG according to the ADA criteria was not associated 
with increased risk for premature mortality.123 
2.4.8 Prediabetes and Brain Function and Cognition 
In large longitudinal studies, fasting glucose has been associated with reduced grey matter in the 
brain in adults.124,125 T2DM in adults has been associated with impaired memory and attention 
performance.124 Adolescents suffering from obesity and T2DM show signs of brain alteration 
compared with adolescents with obesity, but without T2DM.126 Yau and associates compared 8 
obese subjects with T2DM with 18 obese subjects without T2DM using tests for cognitive 
function and fMRI. Adolescents with T2DM consistently performed worse in cognitive domains, 
and brain structural analyses revealed reduced white matter volume, but no obvious grey matter 
volume reduction.126 Taken together, obesity-induced dysglycemia may affect several brain 
functions that are important for schooling.  
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2.4.9 Progression from Impaired Fasting Glycemia to Diabetes 
In the adult population, IFG results in a yearly incidence of T2DM of 5-17% based on various 
IFG definitions and the populations used.112,127-129 The cumulative incidence over 6-9 years has 
been reported with a range of 29-39%.130-132 On the contrary, IFG has also been shown to have a 
reversal rate to normal fasting glycemia (NFG) of 19-80% over 10 years.127,133  
The progression of IFG to T2DM in the pediatric obese population has not previously been 
systematically investigated. However, the transition from the prediabetic stage of IGT to T2DM 
has been shown to be more rapid in children and adolescents compared with adults.134 
2.5 TYPE 2 DIABETES MELLITUS 
2.5.1 Definition 
Type 2 Diabetes Mellitus (T2DM) is caused by the combination of insulin resistance and the failure 
of insulin-producing cells to compensate for the increased needs of insulin release, resulting in a 
diabetic state.55,67 In general, T2DM is not insulin-dependent and is not caused by autoimmune 
destruction of the insulin producing cells, as in type 1 diabetes (T1DM).135 Other types of diabetes 
resemble T2DM, such as dominant genetic forms of non-insulin dependent diabetes, including 
Maturity Onset Diabetes of the Young (MODY) diabetes.136 Latent Autoimmune Diabetes in 
Adults (LADA), a late form of slow-onset autoimmune diabetes, can clinically be interpreted as 
T2DM, but the pathophysiology differs.137 Differential diagnosis are describes in chapter 2.6.  
T2DM is defined equally in adults and children by a fasting plasma glucose ≥7.0mmol/L or a 
plasma glucose of ≥11.1mmol/L two hours after an OGTT.76,77 In contrast to WHO, ADA also 
allows an HbA1c of 48 mmol/L to define T2DM.76 The test should always be confirmed by 
repeated testing before a final diagnosis is made. 
2.5.2 Epidemiology and Risk Factors 
2.5.2.1 Prevalence 
T2DM is a non-communicable disease and a growing public health issue. The International 
Diabetes Federation (IDF) estimated in 2013 that 382 million adults worldwide have some form 
of diabetes, and that the number will increase by 55% to more than 592 million in 2035. The 
situation in Europe is somewhat different, where the increase is estimated to be about 22%, from 
56 million to 69 million. Europe has the highest prevalence of children with T1DM, corresponding 
to about 130 thousand individuals in 2013.138 In Sweden, approximately 323 thousand individuals 
had T2DM in 2014, with 2,460 individuals from the age group ranging from 18-35.139  
2.5.2.2 Risk Factors 
Predicting adult T2DM in young years has been investigated by several prospective cohort studies. 
Demographic, hereditary, and physiological factors have been investigated. On a population basis, 
it is well established that high childhood BMI is associated with adult T2DM.25,101,140-142 The degree 
of obesity in adolescence has also been shown to be higher among those who develop T2DM.134 
Other characteristics associated with increased risk for T2DM are: advancing age, lifestyle (diet, 
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physical inactivity and smoking), ethnicity, and a family history of diabetes.142-144 Morrisson et al 
showed that an elevated fasting glucose level of ≥5.6 mmol/L (IFGADA) in childhood increased 
the odds of remaining IFG or developing T2DM in adulthood almost four-fold.98 
Magnussen et al showed that adolescent presence of the metabolic syndrome that remained into 
adulthood increased the risk for adult T2DM more than 12 times, compared with individuals who 
did not have the metabolic syndrome at either point in time. However, if the metabolic syndrome 
did not last into adulthood, the risk of T2DM was comparable to those who did not have the 
metabolic syndrome at either point in time.145 
Genetic variants have been associated with future T2DM. However, they do not increase the 
prediction of diabetes over clinical risk factors.140 Furthermore, maternal BMI seems to play an 
independent role in the risk for eventual T2DM in the offspring,100 which may be mediated by the 
effect of maternal obesity on the epigenetic modulation of insulin sensitivity in the offspring.146 
2.5.2.3 Consequences and Management 
Early onset of T2DM has been shown to result in rapidly progressing diabetes-related 
comorbidities147,148, and a markedly higher premature mortality rate than T1DM.147,149 In adult high-
risk individuals, T2DM can be prevented by lifestyle changes, including diet and exercise.150 For 
young individuals who develop T2DM, the first line of therapy is a lifestyle modification program, 
including diet and exercise, and pharmacotherapy with metformin.151,152 If needed, insulin therapy 
can be used in the initial treatment phase of the disease.151,152 Pronounced and sustained weight 
loss, for example after obesity surgery, drastically reduces the need for T2DM medication, and for 
subjects with T2DM, a long period of remission can be obtained, especially if bariatric surgery is 
performed soon after T2DM diagnosis.153   
2.6 DIFFERENTIAL DIAGNOSIS OF DYSGLYCEMIA AND TYPE 2 DIABETES  
Previously, hyperglycemia in children was mostly found in T1DM subjects. However, since the 
prevalence of obese children and adolescents with IFG or T2DM is rising, it is important to 
identify the true origin of dysglycemia for each individual so that appropriate therapy can be 
initiated. The following are some other causes of hyperglycemia that should be ruled out. 
2.6.1 Type 1 Diabetes Mellitus  
Most children who develop T1DM are of normal weight and have a history of weight loss before 
diagnosis. However, certain HLA-variants increase the susceptibility to childhood development of 
T1DM with increasing BMI.135 It is therefore important to also keep this diagnosis in mind if the 
child is obese, and to consider the whole clinical picture. If T1DM is suspected, β-cell 
autoantibodies should be evaluated.  
2.6.2 MODY  
Maturity Onset Diabetes of the Young (MODY) represents several single gene mutations and 
accounts for 1–2% of diabetes cases.136 Three genes are responsible for the majority of MODY 
cases: GCK – mutation in the glucokinase gene (previously named MODY 2); HNF1α (previously 
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MODY 3), and HNF4α (previously MODY 1), which involves mutations in the gene hepatocyte 
nuclear factor 1 and 4.  
GCK-MODY is the most common subtype of monogenic diabetes in the pediatric population 
and is characterized by modest hyperglycemia (5.5–8.5 mmol/L) but is otherwise asymptomatic. 
In GCK-MODY plasma glucose does not deteriorate over time, which rarely associates this 
subtype of MODY with microvascular or macrovascular complications of diabetes. Patients do 
not generally require any treatment.154  
For HNF-MODY the prognosis is different, with a gradual increase in plasma glucose over time 
and about the same risk for diabetic complications as T1DM and T2DM, which is why treatment 
with plasma glucose lowering drugs is often initiated.154 
2.6.3 LADA 
Latent Autoimmune Diabetes in Adults (LADA) is probably a slowly progressing variation of 
T1DM that does not require immediate initiation of insulin treatment. The disease is often 
combined with insulin resistance and is generally discovered in adults. Therefore, LADA is easily 
misdiagnosed as T2DM. Compared with T2DM, LADA shows the presence of autoantibodies in 
the blood.137 Hence, patients with LADA share a low insulin sensitivity with T2DM patients, but 
display a more severe defect in beta-cell capacity than patients with T2DM.137 
As many as one third of young people with clinical T2DM have been reported to have 
autoantibodies present. This has raised the question of whether these might be classified as 
“LADY” (latent autoimmune diabetes in youth).155 
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3 AIMS 
 
3.1 GENERAL AIMS 
The overall aims of this thesis were to investigate the prevalence, risk groups, and consequences 
of impaired fasting glycaemia (IFG) in obese children and adolescents. 
 
3.2 SPECIFIC AIMS 
 To investigate the prevalence of IFG and fasting glucose levels among obese children in 
Sweden 
 To study whether IFG and fasting glucose levels differ between regions and between 
northern European countries 
 To investigate factors associated with the risk of IFG in children and adolescents suffering 
from obesity 
 To investigate the predictive value of IFG for future T2DM in children and adolescents 
who have been treated for obesity 
 To evaluate whether the degree of obesity in childhood impacts the risk of T2DM in the 
future 
 To study whether childhood obesity treatment efficacy affects the risk of T2DM in the 
future 
 To investigate whether IFG in the obese pediatric population affects completion of 12 or 
more years in school. 
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4 METHODS 
4.1 STUDY DESIGN AND PARTICIPANTS 
All studies included in this thesis contain data from the Swedish childhood obesity register – 
BarnObesitasRegistret i Sverige (BORIS). BORIS is a national quality register for obesity treatment 
in childhood and adolescence and was initiated in 2005. All studies in this thesis include subjects 
from BORIS. The basic purpose of the registry is to longitudinally follow the treatment of 
childhood obesity and provide working tools. Thus, the quality of childhood obesity care can be 
assured in Sweden. 
BORIS has been supported by the Swedish National Board of Health and Welfare and the Swedish 
Association of Local Authorities and Regions. The register is a good source for epidemiological 
research since it allows for the study of a cohort of individuals with pediatric obesity over time and 
of various ages. 
An overview of the four studies included in this thesis is presented in Table 1. 
4.1.1 Study I 
This study was implemented to investigate the prevalence of IFG in two nationwide cohorts of 
obese children and adolescents. Study I is a cross-sectional observational study that retrieved data 
from the APV register in Germany and the BORIS register in Sweden. Inclusion criteria were 
being 2-17.9 years of age, obese156, with an eligible fasting glucose measurement. Subjects with 
diabetes or usage of metformin, syndromal or secondary obesity and endocrine disorders (except 
for controlled hypothyroidism) were excluded. The first registered fasting glucose measurement 
was used to define IFG. The total number of subjects included from the German cohort was 
n=32,907 and from the Swedish cohort n=2,726. In the German cohort, ~0.04% of the German 
population were included, and in the Swedish cohort, ~0.03% of the Swedish population were 
included. The prevalence of childhood obesity is approximately the same in Sweden and 
Germany.6 Thus, the same proportion of obese subjects is recruited for both registers. 
4.1.2 Study II 
The aim of Study II was to compare fasting glucose levels in young obese children in Poland and 
Sweden. This cross-sectional observational study uses three groups of children: two obese groups 
and one cohort of normal weight. The subjects were obese children in the West Pomerania 
province of Poland who were receiving care for childhood obesity and matched children from 
BORIS. Inclusion criteria were 2-9.9 years of age, obese156, with an eligible fasting glucose 
measurement. Subjects with diabetes or usage of metformin, syndromal or secondary obesity and 
endocrine disorders (except for controlled hypothyroidism) were excluded. Ten subjects from the 
BORIS registry were matched with each child from Poland. Matching variables were age, gender 
and degree of obesity. In addition to the two obese groups, a non-obese control group from 
Sweden was used. The non-obese subjects were originally involved in the STOPP-8 OM3 study at 
Karolinska Institutet, clinicaltrials.gov id: NCT01323283. In total, 109 obese children from Poland, 
1,090 from Sweden, and 86 non-obese children were included.  
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4.1.3 Study III 
Study III evaluated the predictive value of IFG in an obese pediatric population on adult T2DM. 
T2DM medication was used as a proxy for diagnosis. In this prospective study, the obese cohort 
consists of subjects from BORIS. 5-17.9 years of age and obese156 at the first visit for obesity 
treatment at the pediatric clinic or pediatric care center where a fasting glucose measurement was 
documented. Exclusion criteria were obesity syndromes (such as LMBB, PWS), Mb Down or 
deceased before 18 years of age (start of follow-up). A flowchart is presented in Figure 4. A 
comparison group was matched based on gender, year of birth and geographic residence. Through 
a unique national personal identity number routinely assigned to each Swedish resident, a register 
link was initiated for the obese cohort and the matched general population group to data on 
collected prescribed medications. This study included 1,620 individuals from the obese cohort and 
8,046 individuals in the comparison group, corresponding to five controls for each case. 
4.1.4 Study IV 
The aim of Study IV was to investigate the extent to which the obese pediatric population 
completed ≥12 years in school compared with a population-based comparison group. IFG was 
investigated as a risk factor for reduced school completion. Of the obese subjects included in Study 
IV, 877 (60%) had a documented fasting glucose measurement. 
In this prospective cohort study, the source of the obese cohort was subjects included in BORIS. 
A comparison group consisting of five controls for each obese case was matched based on gender, 
year of birth and smallest available geographic residence providing similar socio-economic 
background, randomly selected from the Swedish Total Population Register. The inclusion criteria 
were: obese156 and under 18 years of age at the first obesity treatment visit. At follow-up (2012-12-
31): alive and age ≥20 years, which is at least one year after regular completion of the 12th grade 
in Sweden. The exclusion criteria in both groups were: diagnosed mental retardation, obesity 
syndromes (LMBB and PWS) and Mb Down. A flowchart is presented in Figure 5. 
4.2 MEASUREMENTS AND DEFINITIONS 
4.2.1.1 Obesity and Degree of Obesity (Study I–IV) 
In all studies, obesity was defined according to the International Obesity Task Force (IOTF)156 
taking into account the age, BMI, and gender of the child. The IOTF references are based on large 
nationally representative cross-sectional surveys of growth data from six countries: Brazil, Great 
Britain, Hong Kong, Netherlands, USA, and Singapore.  
In study I, two different BMI standardized age and sex-dependent deviation scores (BMI SDS) 
were used to define the degree of obesity. One reference was based on German children157 and 
one was based on a sample of Swedish children.158 The Swedish reference was also used in Study 
II–IV. Moderate obesity in Study III and Study IV was classified as BMI SDS up to 3.5 and severe 
obesity as BMI SDS of 3.5 or greater, which corresponds to a BMI of approximately 35 in an 18-
year-old adult. 
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Figure 4. Flow-chart of exclusion process in Study III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Flowchart of exclusion process in Study IV. 
 
 
 
  
S
ta
rt
 
E
xc
lu
si
o
n
 p
ro
ce
ss
 
In
cl
u
d
ed
 
n=3320 
n=3301 
n=3147 
n=1596 
n=1504 
n=1465 
Dead n=16 
≥ 18 year at first treatment visit n=82 
Overweight n=75 
 
< 20 year at follow-up (2012-12-31) n=1551 
Syndromes (LMBB, PWS, Mb Down) n=15 
Mental retardation n=77 
Missing registration of residence n=21 
Missing educational information n=18 
S
ta
rt
 
E
xc
lu
si
o
n
 p
ro
ce
ss
 
In
cl
u
d
ed
 
n=3320 
n=2036 
n=1639 
n=1620 
No glucose measurement n=1284 
<5y or ≥18 year at first treatment visit n=69 
Overweight or missing weight status n =328  
Syndromes (LMBB, PWS, Mb Down) n=18 
Dead before follow-up n=1 
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4.2.1.2 Impaired Fasting Glycaemia (Study I–IV) 
The first registered fasting glucose measurement in BORIS was used to identify impaired fasting 
glycaemia (IFG) using both the ADA definition of ≥5.6 mmol/L76 and the WHO definition of 
≥6.1 mmol/L.77 Normal fasting glycaemia (NFG) was defined as ≤5.5 mmol/L. In Study III, 
glucose levels were divided into three groups: Normal ≤5.5 mmol/L, isolated IFG ADA (i-ADA) 
5.6-6.0 mmol/L, IFG WHO ≥6.1 mmol/L.  
4.2.1.3 Regional Divisions (Study I) 
In Study I, a Swedish national cohort was compared with a German national cohort of obese 
children. Germany was divided into four regions: north, south, west (old), and east (new). The 
Swedish cohort was divided into six regions corresponding to counties. 
4.2.1.4 Socioeconomic Status (Study I) 
In Study I, socioeconomic risk in the German cohort was based on unemployment, low level of 
education, and separated parents. Socioeconomic risk was not considered in the Swedish cohort 
due to lack of data. 
4.2.1.5 Ethnicity (Study I, III, & IV) 
In Study I, the impact of ethnicity on IFG was evaluated in the German cohort. Migration 
background was defined as one or both parents having been born outside Germany. 
In Study III and Study IV, subjects were split into two groups based on the countries of birth of 
both the subjects and the parents: Scandinavian – subjects born in Scandinavia with one or two 
parents born in Scandinavia, and Non-Scandinavian – subjects born abroad or born in Scandinavia 
with two parents born abroad. Data was retrieved from Statistics Sweden. 
4.2.1.6 Medical Treatment of Diabetes (Study III) 
The date of the first collected prescribed anti-diabetic drug from 18 years of age was used to define 
the age of onset of diabetes. Groups of antidiabetic drugs were based on the Anatomic Therapeutic 
Chemical (ATC) classification system: all anti-diabetic drugs (ATC A10), subgroups, insulins and 
analogues (ATC A10A) and blood glucose lowering drugs, excluding insulins (ATC A10B). Data 
on collected medicines was retrieved from the Swedish Prescribed Drug Register, which started in 
July 2005. 
4.2.1.7 The Swedish School System and Achieved Educational Level (Study IV) 
In Sweden, children are required to attend school from the age of seven, corresponding to grade 
one. Compulsory school consists of nine years. Most compulsory schools in Sweden are run by 
the local municipality. All people in Sweden who have completed compulsory school are entitled 
to an additional three years of voluntary schooling. Education in grades 10-12 is tailored to either 
practical or theoretical studies, thus providing a good foundation for vocational activities and/or 
further studies. In Sweden, compulsory and voluntary school are both free; students also have 
access to free school health care and school lunches. 
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In study IV, a completed educational level of 12 or more years in school was evaluated. Data on 
the highest completed educational level was retrieved from the Swedish Register of Education, 
held by Statistics Sweden. 
4.2.1.8 Prevalence of ADHD (Study IV) 
Attention deficit disorders (ADHD/ADD) are known to affect school performance and are 
frequently investigated in Sweden. Therefore, registration of ADHD/ADD by international 
diagnosis classification (ICD-10 F90) in the National Patient Register, held by the National Board 
of Health and Welfare, and administration of psychostimulant drugs prescribed for ADHD/ADD 
(ATC N06B) from the Swedish Prescribed Drug Register were used as a proxy for ADHD/ADD. 
4.2.1.9 Age at Start of Treatment (Study IV) 
Age at start of treatment was defined as the first registered visit in BORIS. Subjects’ ages at start 
of obesity treatment were divided into four groups: 5.0-9.9 years, 10.0-13.9 years, 14.0-15.9 years, 
and 16.0-17.9 years of age.  
4.2.1.10 Obesity Treatment Efficacy (Study IV) 
Treatment efficacy, based on change in relative weight (BMI SDS), was calculated by subtracting 
the first registered measurement from the last registered BMI SDS in BORIS. Children who stayed 
in treatment for less than 12 months were defined as early dropouts.  
4.2.1.11 Obesity Treatment Duration (Study IV) 
Data on obesity treatment duration was retrieved from BORIS. Time spent in treatment was 
divided into four categories: 1-2 years, 2-3 years, 3-5 years, and 5 years or more. As in the variable 
treatment efficacy, subjects who stayed in treatment for 12 months or less were defined as early 
dropouts. 
4.3 STATISTICAL ANALYSIS 
Table 2 presents the statistical methods used in the studies. In Study I, the statistical software 
Statistica, Version 10.0 (Stat Soft, Inc. Tulsa, OK, USA) was used. In Study I, II, III and IV SAS 
Version 9.3 and Version 9.4 (SAS Institute, Cary, NC, USA) was used. In addition, in the thesis, 
Kernel distribution and receiver operating characteristic (ROC) curve were used. The significance 
level was set at α=0.05, 95% confidence limits. 
Table 2. Statistical methods used in each study. 
 Study I Study II Study III Study IV 
Descriptive statistics x x x x 
Linear regression x x   
Logistic regression x   x 
T-test independent samples  x  x 
Chi square test   x x 
Cox regression   x  
Kaplan Meier curve   x  
  25 
4.4 ETHICAL APPROVAL 
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5 RESULTS 
5.1 PREVALENCE OF IFG (STUDY I AND II) 
The overall prevalence in the Swedish cohort (n=2,726) of IFGADA was 17.1% and IFGWHO 3.9%. 
The corresponding numbers in the German cohort (n=32,907) were 5.7% and 1.1%. Compared 
with Germany, the prevalence of IFG among obese children and adolescents in Sweden was three 
times higher according to ADA criteria and 3.5 times higher according to WHO criteria. When 
evaluating the unadjusted prevalence in subgroups (Table 3), the youngest age group had the lowest 
prevalence and subjects with the highest degree of obesity had the highest prevalence in both 
cohorts. 
The combination of data on children <10 years from Study I and data from Study II revealed the 
prevalence of IFGADA to be 2.5 times higher in the Swedish obese population compared with both 
German and Polish obese populations. The differences were not as pronounced for IFG according 
to the WHO criteria. No subjects in the non-obese Swedish population had elevated fasting 
glucose levels. Table 4 presents the prevalence of IFG in children under 10 years of age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Prevalence of IFG by gender, age, and degree of obesity158 
 Germany 
n=32,907 
Sweden 
n=2,726 
 % IFGADA % IFGWHO % IFGADA % IFGWHO 
Overall 5.7 1.1 17.1 3.9 
Girls 5.2 1.0 16.1 3.3 
Boys 6.2 1.2 17.9 4.3 
p <0.001 0.28 0.22 0.16 
Age     
Age 2 - <9 y 4.3 0.9 10.9 1.7 
Age 9 - 12.9 y 6.0 1.2 18.7 3.4 
Age 13 - 15.9 y 6.0 1.1 18.8 5.4 
Age 16 - 18 y 5.3 0.8 21.5 5.5 
p <0.001 0.09 <0.001 <0.001 
BMI SDS      
BMI SDS <2.5 5.0 1.0 11.8 2.6 
BMI SDS 2.5- <3.0 5.3 1.0 14.1 3.0 
BMI SDS 3.0 - <3.5 6.0 1.1 16.8 4.4 
BMI SDS 3.5 - <4.0 6.7 1.2 20.4 5.0 
BMI SDS 4.0 - <4.5 6.7 1.7 18.5 2.9 
BMI SDS ≥4.5 6.1 1.4 22.2 2.8 
p <0.001 0.23 0.02 0.35 
Adopted from Hagman et al. IJO 2014 
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Table 4. Prevalence of IFG among obese and non-obese children under 10 years. 
 IFG ADA IFG WHO 
 Study I Study II Study I Study II 
Sweden (obese) 10.9% 9.1% 1.7% 2.1% 
Germany (obese) 4.3%  0.9%  
Poland (obese)  3.7%  1.8% 
Sweden (non-obese)  0%  0% 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 RISK FACTORS FOR IFG (STUDY I) 
Risk factors for IFG in children and adolescents in Study I included higher age and more severe 
degree of obesity. Boys had a slightly higher risk of IFGADA. However, the largest independent risk 
factor investigated was living in Sweden, which had an adjusted odds ratio of 3.4 [3.0–3.8]. Table 
5 presents adjusted odds ratios. 
When investigating the impact of ethnicity in the German cohort, immigration background did 
not affect the risk of IFG. Regarding regional differences in each country, the risk of IFGADA was 
elevated in western Sweden (Västra Götaland) compared with most other regions. In Germany, 
eastern states had a higher risk of IFG than western states. No explanatory reasons for this 
association could be found. 
  
 
Table 5. Odds ratios for IFG, adjusted for gender, age group, and BMI SDS158, n=35,633. 
 OR 
IFG ADA 
(95% CI) OR 
IFG WHO 
(95% CI) 
Age 2–<9 years 1.00 ref 1.00 ref 
Age 9–12.9 years 1.73 (1.48–2.02) 1.79 (1.27–2.51) 
Age 13–15.9 years 1.77 (1.51–2.07) 1.93 (1.37–2.72) 
Age 16–18 years 1.50 (1.24–1.81) 1.33 (0.87–2.02) 
BMI SDS 2.3–2.5 1.00 ref 1.00 ref 
BMI SDS 2.5–<3.0 1.04 (0.94–1.14) 1.04 (0.80–1.34) 
BMI SDS 3.0–<3.5 1.20 (1.06–1.36) 1.15 (0.85–1.54) 
BMI SDS 3.5–<4.0 1.44 (1.25–1.66) 1.39 (1.00–1.93) 
BMI SDS 4.0–<4.5 1.54 (1.25–1.91) 1.74 (1.11–2.73) 
BMI SDS ≥4.5 1.83 (1.36–2.47) 1.79 (0.92–3.45) 
Boys vs Girls (ref ) 1.13 (1.03–1.22) 1.09 (0.91–1.31) 
Sweden vs Germany 3.40 (3.04–3.81) 3.66 (2.92–4.60) 
Bold numbers indicate statistically significant differences. Adopted from Hagman et al. IJO 2014 
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5.3 DISTRIBUTION OF FASTING GLUCOSE LEVELS (STUDY I AND II) 
In Study I, the two populations were between 2-18 years of age. Higher prevalence of IFG in the 
Swedish cohort compared with the German cohort was mirrored in a generally higher distribution 
of glucose levels, mean (SD) glucose level of 5.05 (0.52) mmol/L vs. 4.64 (0.58) mmol/L 
(p<0.0001), as illustrated in Figure 6. In Study II, the three populations were all under 10 years of 
age. The mean fasting glucose values of the Polish, Swedish and non-obese cohorts were 4.73 
(0.51) mmol/L, 4.92 (0.50) mmol/L and 4.56 (0.39) mmol/L, respectively. After adjusting for 
variables affecting fasting glucose, the mean glucose value of the Swedish obese children was 0.20 
mmol/L higher than that of Polish obese children (p < 0.0001) and 0.41 mmol/L higher than in 
non-obese controls (p < 0.0001). 
A comparison of data from Study I and Study II revealed no differences between German obese 
children between 2-18 years of age and the Swedish sample of non-obese children under the age 
of 10 (p=0.07). Nor did the obese German cohort differ from the Polish subjects under the age 
of 10 (p=0.1). Figure 6 presents mean and SD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Kernel-distribution and descriptive data of glucose levels in the cohorts in Study I and Study II. 
 
 
  n Mean glucose SD 
 Germany 2-18y 32,907 4.64 0.58 
 Sweden 2-18y 2,726 5.05 0.52 
 Sweden <10y 1,090 4.93 0.49 
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 Non-obese <10y 86 4.56 0.39 
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5.4 PREDICTION OF ADULT TYPE 2 DIABETES MEDICATION (STUDY III) 
5.4.1 Subjects Prescribed T2DM Medication 
In total, 1,620 subjects from the obese cohort were eligible and matched with 8,046 subjects, 
henceforth called the comparison group. The proportion of subjects that collected specific T2DM 
medications (ATC A10B) were 3.2% (n=52) in the obese cohort and 0.1% (n=11) in the 
comparison group (p<0.0001). Figure 7 presents crude proportions of subjects collecting T2DM 
medications split into groups based on baseline glucose levels. Figure 8 presents Hazard Ratios 
(HR), adjusted for gender, degree of obesity, and ethnicity, for glucose levels, showing that the HR 
does not tend to increase before glucose levels above of 5.8 mmol/L, HR=3.0 [0.7-13.4] and is 
statistically different when glucose levels rise to 5.9 and above, HR=5.75 [1.63 – 20.26]. 
 
In Cox regression, adjusted for gender and ethnicity, the collection of T2DM medications differed 
considerably between the groups with a HR of 24.0 [12.5-46.0] (p<0.0001). When normoglycemic 
(<5.6 mmol/L) obese subjects were compared with the comparison group, adjusted HR was 18.49 
[9.29–36.80] (p<0.0001). Neither gender nor ethnicity affects the risk of T2DM medication usage. 
Crude cumulative incidence of collection of T2DM medication is shown in Figure 9. 
 
 
 
Figure 7. Proportion of type 2 diabetes medication usage in adulthood, divided into levels 
of glucose at childhood and a comparison group, matched based on gender, age, and living 
residence.  
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Figure 8. Hazard Ratios (HR) across glucose levels in the obese cohort, using <4.5 mmol/L 
as reference. The model is adjusted for gender, degree of obesity, and ethnicity. 
 
 
 
 
Figure 9. Cumulative incidence of type 2 diabetes medications (ATC A10B) in young adulthood 
among individuals who have been treated for obesity in childhood. They are divided based on 
fasting levels of glucose at childhood and compared with a group, matched on gender age and 
living area. Numbers to the right in brackets indicate numbers of individuals left in each strain at 
26 years of age. 
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5.4.2 IFG According to ADA or WHO and Collected T2DM Medication 
In adjusted models for collecting T2DM medications, HR for IFGADA was 1.67 [0.82 – 3.42] 
(p=0.16) and for IFGWHO HR=3.84 [1.93–7.67] (p<0.0001). Women were twice as likely to collect 
prescribed T2DM medications, but an even greater impact was seen among those with a severe 
degree of obesity (≥3.5 BMI SDS). These subjects were more than twice as likely to collect T2DM 
medications. Ethnicity did not affect the outcome in any of the models. Hazard ratios are presented 
in Table 6. 
 
Table 6. Hazard Ratios (HR) for collecting T2DM specific medications in the obese cohort n=1,620. The 
models are adjusted for IFG (i-ADA, 5.6-6.0 mmol/L, in Model 1 and WHO, ≥6.1 mmol/L, in Model 2), 
gender, ethnicity and severity of obesity. 
 Model 1 Model 2 
 HR 95% CL p HR 95% CL p 
IFG (i-ADA) vs NFG 1.67 0.82 – 3.42 0.159    
IFG (WHO) vs NFG    3.84 1.93 – 7.67 <0.0001 
Girls vs. Boys 1.91 1.00 – 3.66 0.050 2.03 1.05 – 3.91 0.0349 
Non-Scandinavian vs. Scandinavian 1.24 0.62 – 2.49 0.537 0.93 0.46 – 1.90 0.842 
Severe vs. Moderate degree of obesity 2.37 1.26 – 4.47 0.008 2.66 1.42 – 4.97 0.002 
 
5.4.3 The Impact of Obesity Treatment on T2DM Incidence 
Subjects who had a poorer obesity treatment effect during the pediatric years had higher incidence 
of collecting T2DM medications in adulthood, adjusted HR=2.37 [1.25–4.48] (p=0.008) for each 
1 unit increase in BMI SDS. This is illustrated in Figure 10. 
 
5.5 IFG AND SCHOOL COMPLETION (STUDY IV) 
In the obese cohort, 55.4% completed ≥12 years in school, compared with 76.2% in the 
comparison group (p<0.0001). Subjects with severe obesity had a lower completion rate compared 
with subjects with moderate obesity. Girls were more likely to be completers in both cohorts, while 
being of non-Scandinavian origin marginally influenced the outcome in the obese cohort.  
The proportion of IFGADA was 22.7%, and IFGWHO was 7.1%. In crude models, IFG did not 
correlate significantly with school achievement. Completion of ≥12 years in school was 50.8% for 
those with i-IFGADA, and 48.4% for IFGWHO, compared with 55.8% for non-IFG, see Figure 11. 
Adjusting for gender, age, degree of obesity, ethnicity, having non-IFG, IFGADA, or IFGWHO did 
not significantly affect the possibility of completing ≥12 years in school (P for all analyses >0.09). 
When analyzing glucose as a continuous variable, a non-significant tendency on school completion 
could be seen (adjusted p=0.06). 
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Figure 10. Percentage of individuals who have been treated for obesity in childhood 
collecting T2DM medications in young adulthood. They are divided into four groups 
depending on treatment effect based on BMI SDS change obtained from first to last 
registered BMI (n=1167).  
 
 
 
Figure 11. Crude percentage of subjects achieving ≥12 years in school. A non-
significant trend towards lower proportion of schooling across fasting glucose 
levels. 
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6 DISCUSSION 
6.1 MAIN FINDINGS 
 IFG is highly prevalent among children and adolescents with obesity in Sweden. IFGADA 
(fasting glucose ≥5.6 mmol/L) affects more than 1 in 6 children with obesity in Sweden.  
 Higher age and degree of obesity are risk factors for IFG. Boys are slightly more at risk for 
IFG. 
 There are large international differences. After adjustments, children with obesity in Sweden, 
due to unknown reasons, have a 3 to 4-fold higher risk of having IFG than children in 
Germany, and a 2.4-fold higher risk compared with children in Poland. 
 IFGWHO (fasting glucose ≥6.1 mmol/L) but not the additional interval added by ADA (5.6-
6.0 mmol/L) in the obese pediatric population is associated with increased risk for adult 
pharmacological treatment of T2DM. 
 IFG in the obese pediatric population is not significantly associated with achieved educational 
level in Sweden, whereas severe obesity is associated with a markedly reduced educational 
level. 
6.2 PREVALENCE OF IFG IN THE OBESE PEDIATRIC POPULATION 
The prevalence of IFG in obese children and adolescents seems to vary considerably across 
different obese pediatric populations. Reported prevalence of IFG ranges from zero to almost 
50%.86,87 In Study I, the prevalence of IFG was compared in Germany and Sweden under similar 
conditions. Degree of obesity was calculated the same way and the source of the populations 
studied in Sweden and Germany were children seeking medical help for obesity. We also studied 
IFG defined both according to ADA and WHO. From this study, it is therefore possible to 
conclude that there are true international differences in IFG prevalence in the obese pediatric 
population. In Study II, a 2.4-fold higher prevalence of IFG was found among Swedish children 
compared with Polish children. Interestingly, data from another research group in Sweden recently 
reported marked differences in IFG prevalence in children suffering obesity between the town of 
Uppsala, Sweden and Salzburg, Austria159, which seems to confirm our results.  
6.3 THE USE OF ONLY ONE GLUCOSE MEASUREMENT  
In epidemiological studies, diagnosis of diabetes is often made upon one test only. In clinical 
situations, a diabetes diagnosis has to be confirmed with a second test. It is known that IFG is a 
fickle condition, when normal fasting glucose levels may be present between periods of IFG.77 In 
a sample of 60 overweight youth the mean absolute difference between two fasting glucose tests 
was 0.24 mmol/L, and ranged between 0-0.72 mmol/L.160 The reproducibility of IFG in adults 
has been shown to have a к-value of 0.44-0.56161, which is considered to be a moderate 
agreement.162 A high fasting glucose that is not reproduced could suggest that a tendency towards 
high fasting glucose might reflect a vulnerability of dysglycemia. With that argument, one fasting 
glucose measurement should be acceptable for larger epidemiological studies. However, repeated 
measurements probably enhance the precision of prediction of T2DM. 
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Another aspect that must be considered is that fasting glucose levels depend on living conditions 
the day before measurement. Both the degree of physical activity and food choices prior to blood 
sampling will affect overnight fasting glucose measurement.163 Thus, ideally, food intake and 
physical activity should be standardized one to two days before the fasting glucose measurement. 
As this is not feasible, single fasting glucose levels should be handled with caution in individual 
cases. 
6.4 ARE FASTING GLUCOSE CUT-OFF LEVELS REASONABLE? 
Is the desire to categorize individuals as ill or healthy helping or hindering the clinical investigation 
of an individual? Cut-offs may be comfortable to use, but they do not take into account normal 
individual variability or risk susceptibility. Therefore, cut-off levels should be interpreted with 
caution on an individual level. There are also some downsides on the population level to be aware 
of. A cut-off for prediabetic stages assumes that the entire population, regardless of ethnicity, age, 
and gender, has the same relationship between early signs of dysglycemia and T2DM, which may 
not be the case, as I have shown here. A lower cut-off will of course increase the sensitivity, i.e., 
identifying the true positive rate that will develop T2DM, since the definition is more inclusive, 
but on the coast of specificity, i.e., the true negative rate. 
Individuals from different ethnic backgrounds with the same BMI may have different body 
compositions and display different levels of vulnerability to metabolic comorbidities.164 For 
example, Asians have a higher percentage of body fat than Caucasians with the same BMI.165 This 
indicates that subjects with a similar degree of obesity based on BMI may be different when it 
comes to their degree of insulin sensitivity.164,166-168 Furthermore, certain ethnic groups, i.e. African 
Americans, seem to be more susceptible to developing dysglycemia.113 There are also large 
variations in the patterns of sexual maturation between boys and girls, which affect insulin 
resistance, within and between populations.169,170  
The Bogalusa Heart study showed, with a community-based population, in normoglycemic (< 5.6 
mmol/L) children that the optimal cut-off that predicts future diabetes is 4.8 mmol/L. Further 
Nguyen et al concluded that the risk of developing diabetes in adulthood was more than twice as 
high with a plasma glucose of 4.7 to 5.5 mmol/L compared to less than 4.7 mmol/L.171 However, 
since no child had a fasting plasma glucose of 5.6 mmol/L or above, it is impossible to estimate 
from this study what IFG leads to. Nevertheless, it is rational to assume from this study that 
childhood dysglycemia might have a different prognostic impact than adult dysglycemia. When 
evaluating the population included in Study III, it is not possible to find a rational glucose cut-off 
for the prediction of future T2DM (Figure 13). 
Further, one might speculate that those who are diagnosed with IFG and informed about it will 
adopt a healthier lifestyle. However, such evidence is not available to the best of my knowledge. 
Additionally, labeling subjects with a prestage of diabetes might affect the cost or possibility of 
health insurance in some countries.172  
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6.5 CONTINUOUS VALUES OF GLUCOSE  
The glucose levels that define IFG are somewhat arbitrary, where 100 mg/dL (5.6 mmol/L) and 
110 mg/dL (6.1 mmol/L) have been decided to use. A rise in glucose level over time follows a 
continuous pattern, and therefore, an increase in fasting glucose levels could be observed with 
caution regardless of which cut-off point is used. Some studies have even suggested lowering the 
threshold, since a level of 5.2 mmol/L, which is below both IFG definitions, has been shown to 
increase the risk for future diabetes.173 Shaw et al demonstrate that the risk for future diabetes 
increases with increasing fasting glucose levels, which is logical. Furthermore, they show that 5.4-
5.5 mmol/L is the optimal cut-off for predicting T2DM over a 5 year period, when sensitivity and 
specificity are optimized.174  
Others have instead pointed out that by lowering the cut-off from 6.1 to 5.6 mmol/L results in a 
two to five-fold increase of IFG prevalence in most populations, and the public health aspects of 
that have yet to be evaluated.175 Since IFGADA in adults not only increases the risk for T2DM, but 
also the risk for CVD and cancers119,120 one could suggest that IFGADA should be treated or 
followed closely over time. In that case, it has to be shown that such actions reduce morbidity and 
the cost of such interventions both for the individual and for the society must be evaluated.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. ROC Curve for the predictive value of pediatric fasting glucose and 
adult incidence of T2DM medication. Glucose value of 5.6 mmol/L and 6.0 are 
indicated in the graph. Area under the curve = 0.65.  
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6.6 CHALLENGES WHEN MEASURING GLUCOSE CONCENTRATION 
Glucose concentration is usually measured in whole blood or in plasma. Plasma glucose is 
preferred over whole blood, due to its independence from hematocrit.176 If glucose concentration 
is measured in whole blood, it could be recalculated to plasma glucose, at normal hematocrit, by 
the factor of 1.11.177 Further venous plasma glucose is preferable over capillary tests46. Generally, 
whole blood samples display a lower fasting glucose concentration compared with venous plasma 
measurements, and a higher or equal concentration of 2h after an OGTT.178,179 As an example: a 
venous plasma glucose of 6.1 mmol/L corresponds to a capillary whole blood concentration of 
5.6 mmol/L, according to WHO.179 The differences between venous and capillary whole blood 
are not as pronounced in the fasting state.179,180 Physiological factors and pre-analytical factors, such 
as time from sampling to analysis, and the kind of glycolysis inhibitor used in the tubes can affect 
the glucose concentration.181,182 Differences in glucose concentration due to pre-analytical factors 
can be up to 0.5 mmol/L.180-182 
6.7 FACTORS AFFECTING THE RISK FOR DYSGLYCEMIA 
6.7.1 The Impact of Degree of Obesity 
It has been shown that children with overweight and obesity are at increased risk of IFG compared 
to normal weight peers.86,91,94 Based on the assumption that IFG is a prediabetic stage, it is unlikely 
that IFG prevalence does not increase with increasing BMI, since T2DM is heavily dependent on 
obesity and insulin resistance, although T2D may also occur among subjects with BMI in the high 
normal range.183  
To my knowledge, Study I of this thesis was the first study to show that not only obesity, but also 
the degree of obesity, increases the risk for IFGADA in children and adolescents. We observed that 
degree of obesity increased the risk for IFGADA but not IFGWHO. Although it can be due to an 
insufficient power, as IFGWHO has a lower prevalence, this might indicate that the highest levels of 
fasting glucose might be caused by genetic/epigenetic glucose homeostasis vulnerability in 
combination with obesity, rather than an effect of obesity per se. 
6.7.2 The Impact of Age 
In Study I, there was an increasing IFG prevalence with higher age in Sweden and Germany. In 
Study II, the IFGADA prevalence among Polish children under 10 years of age was 3.7%. Another 
study in older Polish children and adolescents displayed an IFGADA prevalence of 15.2%
184, which 
indicates that increasing age or pubertal progression is an important risk factor in the Polish obese 
pediatric population as well. 
In Study I, the odds ratio for IFG appears to decrease in the highest age group (16-18 years) 
compared with the younger age group (13-16 years). This might be due to selection bias. It could 
be hypothesized that adolescents who start obesity treatment close to adulthood have not had 
obesity for as long and are therefore not as metabolically affected as the children and adolescents 
that receive obesity treatment at younger age.  
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Another reason might be that it reflects normal physiology to some extent. The insulin resistance 
induced by puberty69 in combination with insulin resistance induced by obesity might increase the 
number of cases classified as IFG during that period of development. Assuming that obese 
adolescents also improve their insulin sensitivity, it could be mirrored by a lower prevalence of 
IFG among older adolescents who are more likely to have passed puberty. However, if IFG shall 
be considered a prediabetic stage, it is likely that the prevalence increases with age, as the risk of 
developing T2D also increases with age.  
6.7.3 The Impact of Gender 
In Study I, boys were shown to be more prone to have IFG, but the magnitude of gender 
differences for IFG risk was very small. The same pattern was seen when continuous fasting 
glucose levels were investigated in Study II, even though the population herein was under 10 years 
of age and most likely prepubertal. This is consistent with other published data on obese pediatric 
populations88,92 , but not all.89 However, in population-based samples the prevalence of IFG is 
estimated to be much higher in boys than in girls.91,94 
Contrary to the higher prevalence of IFG in boys, women in Study III collected more T2DM 
medications than men, which is analogous to some19,130, but not all earlier studies.130 It remains 
unclear whether IFG is more dangerous or progresses faster in women, or if women are likelier to 
receive these kinds of medications for some other reason. In adults, undiagnosed T2DM is more 
common in men185, and young women may seek medical help more often186 due to family planning 
problems. Nevertheless, women seem to be more prone to developing T2DM independently of 
other risk factors such as BMI, physical activity, and SES.187 Adherence to T2DM medication does 
not seem to differ between the genders.188 
6.7.4 Genetic and Epigenetics 
Genetic variations have been shown to affect fasting glucose levels in both healthy adults and 
children.189-191 It was recently reported that a common variant of melatonin receptor 1B gene is 
associated with increased risk of IFG in children and adolescents with obesity.192 
Epigenetics include methylation of DNA, which plays an important role in regulating gene 
expression. This is also the case for the expression of genes essential for the maintenance of normal 
glucose levels.193 Environmental factors and natural physiological changes in childhood affect 
epigenetic patterns.194,195 In T2DM, a defect in DNA methylation is suggested. It has been observed 
that S-adenosylmethionine (SAM), the main physiological donor of methyl groups, is decreased in 
erythrocytes of diabetic patients. In addition, decreased concentration of SAM in erythrocytes has 
been found to be associated with progression of the disease.196 In a recent study of 11 individuals 
with IFGADA who developed T2DM, the authors suggest that epigenomic changes involving both 
hyper and hypomethylation may be involved in the progression from IFG to T2DM.197 
Transgenerational epigenetic effects of diet may be passed on to future generations. In a study of 
historical records from Överkalix, a northern parish in Sweden, the grandsons of men who were 
well-nourished prior to puberty had an increased risk of developing T2DM.193 
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6.7.5 Does IFG Have Different Origins? 
It is possible that IFG only to some extent in children and adolescents causes or is caused by 
factors associated with T2DM comorbidity. This seems plausible especially in the exclusive ADA 
range. Thus, we hypothesize that elevated glucose levels have two origins, one is caused by obesity 
and/or obesity comorbidities and one is caused by other environmental/epigenetic factors. We 
also hypothesize that the latter is not associated with obesity comorbidities or increased risk for 
T2DM. 
There are several observations supporting these hypotheses. As seen in Study I and Study II, there 
are marked regional differences in IFG prevalence that persist after adjustment for possible 
confounders. We have no explanations for this regional variation. In addition we have no 
indication that T2DM prevalence in adolescents is higher in Sweden than in other countries despite 
very high IFG prevalence and silent diabetes seems to be unusual.198 Furthermore, in Study III we 
cannot detect any association between IFG ADA in children and use of T2DM medication in 
young adults.  
In theory, there are three possible explanations for the combination of high prevalence of IFG 
and low prevalence of T2DM 1) there are protective factors reducing the progress from 
prediabetes to T2DM in Swedish children resulting in low prevalence of T2DM despite high 
prevalence of IFG. However, this combination seems unlikely 2) the progress from prediabetes to  
T2DM is slower in children in general than in adults, as discussed in chapter 6.8, and 3) the high 
fasting glucose levels observed in Swedish children are, at least partly, not associated with obesity 
co-morbidity. This theory is supported by the observation that normal weight children in Study II 
had fasting blood sugar levels in the same range as obese children from Germany in Study I.  
It has been shown that IFG in adults, even without progress to T2DM, is associated with increased 
co-morbidity.120 However, the causal relationship between moderately elevated glucose levels and 
morbidity can be questioned as there are data form some populations indicating that high fasting 
glycemia in itself does not cause increased morbidity and mortality in adults. Subjects with 
mutations in the glucokinase gene (MODY 2) display elevated fasting glucose levels in the IFG 
and diabetes range without any increased risk for diabetes-related comorbidities. Therefore it is 
recommended that this type of diabetes should not be treated.154 Thus, given that the clinical 
information obtained from patients with glucokinase mutations is relevant for IFG, it is not the 
elevated glucose levels per se, but factors causing it that are of importance as drivers of morbidity 
and mortality. If we hypothesize that IFG in some obese children in Sweden is caused by other 
factors, not associated with obesity co-morbidity, these children should not have increased risk for 
T2DM over normoglycemic obese children.  
However, it is possible that other disease risks are associated with regional/cultural factors causing 
higher fasting glucose levels. T1DM is far more prevalent in Sweden than in Germany and 
Poland199 and one might speculate that similar regional factors both affect the risk for IFG in obese 
children and the risk for T1DM. 
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6.7.6 Ethnic Differences 
Ethnicity is a multifaceted concept for which consensus for the concept does not exist. Ethnicity 
includes several aspects, such as geographical, social, historical and cultural factors, linguistic 
background, lifestyle, and religion. Consequently, ethnicity is a highly changing factor that could 
be influenced by migration.200 Further, migration studies might investigate ethnic characteristics 
caused by genetic disposition and what is controlled by environmental factors. A classic example 
is short stature among Japanese compared with Caucasians, which was long perceived as a genetic 
condition, but since the second-generation Japanese people in the United States have the same 
average height as Americans in general, it is clear that the short stature is conditioned by 
environmental factors.201 This demonstrates that ethnicity and genetics should be considered 
separately in epidemiological research. 
In Study I, we investigated the impact of ethnicity in the German cohort and found no difference 
in IFG prevalence between Germans and immigrants. Other studies have been able to evaluate 
the impact of different origins within the same country more closely. Van Vliet and colleagues 
found differences in the prevalence of IFG among children with overweight or obesity living in 
the Netherlands with different country backgrounds. They found that children of Moroccan origin 
had an IFG prevalence of 25%, Turkish origin 20%, and native Dutch 12% IFG.90 Other studies 
have also shown marked ethnic differences of IFG in obese children96,97, while another could not 
detect differences in fasting glucose in obese pediatric subjects across different ethnic origins.86,94 
It is possible that there are ethnic differences in both Sweden and Germany that we could not see 
due to the wide definition used. However, not seeing the ethnic impact on IFG risk but regional 
differences, such as those between former east and west Germany, might indicate that other 
factors, such as degree of obesity or eating habits, are of greater importance. Interestingly, 
environmental factors rather than ethnicity seem to explain the prevalence of type 1 diabetes in 
Sweden.202 
Both Study I and Study II and new data from another research group159 lead us to believe that 
glucose levels are generally higher in Sweden than in middle European countries. It is noteworthy 
that non-obese children in Sweden do not have lower fasting glucose levels than obese children 
and adolescents in Germany and Poland, raising a theory that non-obese children in Sweden have 
higher fasting glucose levels than non-obese children in middle Europe. However, this is still to be 
investigated.  
Causes which could contribute to prevalence differences within or between populations might 
include differences in early dietary patterns, physical activity, levels of vitamin D203, genetics108,204, 
as well as viral infections linked to obesity and insulin resistance.12 
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6.8 IS IFG IN THE OBESE PEDIATRIC POPULATION REALLY A PRESTAGE 
OF T2DM? 
In Study III of this thesis there was demonstrated a 24-fold increased risk for T2DM medication 
in the obese cohort compared with the comparison group. Further, subjects with severe obesity 
had more than twice the risk compared with subjects with moderate obesity. It has also been shown 
that not only obese, but also overweight adolescents without any apparent metabolic disturbance 
have a 6-fold increased risk of T2DM more than 20 years later, compared with normal weight 
controls.25 Thus, these data clearly demonstrate that the degree of overweight and obesity is of 
importance for later development of T2DM. 
The association between fasting glucose levels and future risk of T2DM seems to be more 
complex. In Study III, obese children and adolescents with fasting glucose within the exclusive 
IFGADA range (5.6-6.0 mmol/L) did not have significantly higher incidence of collecting prescribed 
T2DM medication in adulthood than obese children who were normoglycemic. It has previously 
been shown in a pediatric population that increased fasting glucose levels already within the 
normoglycemic range (<5.6 mmol/L) are a risk factor for future T2DM.171 However, these results 
are probably not contradictory, as Study II shows that obese children in general have slightly higher 
fasting glucose levels than normal weight children. It is therefore possible that obesity and 
overweight contribute to the difference in T2DM risk observed in the population-based study of 
fasting glucose and future diabetes risk.171 In Study III of this thesis, it was observed a risk 18.5 
times higher for T2DM medication among obese children and adolescents with normoglycemia 
than in the population-based comparison group. When the HR were studied across the span of 
glucose concentration, no clear-cut increase could be observed before 5.8 mmol/L (Figure 8). 
Additionally, no clear-cut protective effect could be observed in the low glucose range. Thus, our 
data indicate that IFGADA is not a prediabetic stage in children and adolescents with obesity.  
Assuming that all subjects in the comparison group who collected T2DM medication (0.14%) are 
obese, and assuming the same proportion of obese subjects collect T2DM medication (3.21%), it 
would correspond to an obesity prevalence in the comparison group of 4.3%, which is about the 
general obesity prevalence in children and adolescents.4  
In 2014 in Sweden, only 52 youths (up to 18 years of age) were diagnosed with T2DM205 and in 
the age group of 18-35 year-olds, 2,460 individuals were diagnosed with T2DM.139 Since Study I 
reveals that 17% of obese children have IFGADA and approximately 5% of children in Sweden are 
obese1, the number of T2DM diagnoses in adolescents are not as frequent as what one would 
expect. Taken together, this might indicate that the progress from IFG to T2DM in adolescents is 
slow – provided that IFGADA truly is a prediabetic stage! On the other hand, IGT in severely obese 
adolescents has been shown to have a rather fast progression to T2DM.134 With the additional 
knowledge from the present study, we can conclude that the progression from IFG in the obese 
pediatric population to adult T2DM is not as pronounced as from IGT in childhood or IFG in 
adults. 
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Although the progression of IFG to T2DM may be slow in adolescents, the progress of the severity 
of the disease is very fast, as well as the progress of T2DM-related comorbidities. The Swedish 
DISS-study showed that 16% of 30-year-old subjects who have developed T2DM also developed 
renal complications.148  
6.8.1 Children are not Small Adults 
In the adult population, IFG results in a yearly incidence of T2DM of approximately 3.5% for IFG 
ADA206 and up to 34% for IFG WHO%.112,127 In Study III of this thesis, the incidence is much 
lower. This may indicate that IFG in children and adolescents is associated to a lesser extent with 
high risk of T2D development than in adults. There are several potential causes for that and the 
reasons are most likely multifactorial. 
Insulin resistance is a part of T2DM progression, and onset of this syndrome may occur already 
in childhood.13,207 However, children normally experience transient insulin resistance during 
puberty. In normal weight children, an immediate increase in insulin resistance occurs at the onset 
of puberty (Tanner stage 2), to return to near prepubertal levels by the end of puberty (Tanner 
stage 5). The physiologically normal insulin resistance peak occurs at mid-puberty (Tanner stage 3) 
in both boys and girls. However, girls seems to be more insulin resistant than boys at all Tanner 
stages.208 Insulin sensitivity is also affected by puberty in the obese pediatric population.13  
Another possible reason for prolonged progression from IFG to T2DM might include an 
adaptation to metabolic changes induced by early obesity. In children, microvascular changes 
related to obesity have been inversely associated with the duration of obesity209, which indicates a 
possible adaptation to early cardiovascular changes. One can hypothesize that this is also the case 
for dysglycemic progression, which, in that case, could explain the prolonged progression to 
T2DM. 
One must also keep in mind that T2DM was originally a disease of the elderly. Epidemiological 
evidence shows that psychosocial stress, primarily linked to adult life, such as work-related stress, 
is linked to T2DM.210,211 Other attributes, such as tobacco consumption, which has also been linked 
to T2DM incidence212,213, are adult related cues.  
6.8.2 Medication as a Proxy for Disease 
A prescription is needed in Sweden for all T2DM medication. The prescribed drug register, which 
is used in Study III, has information about medications that have been prescribed by a medical 
doctor and collected by the patient. It remains unknown whether the patient has taken the medicine 
or if there is a satisfying adherence during the time treated. Furthermore, there is no guarantee that 
the T2DM medication has not been prescribed for other implications than T2DM, such as PCOS 
or prediabetes, although prediabetes is not a disease. 
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6.9 IFG AND SCHOOL COMPLETION 
In Study IV, pediatric obesity was associated with a strikingly lower achieved educational level in 
early adulthood compared to a population-based matched comparison group. In the obese cohort, 
IFG was investigated as a metabolic perturbation hypothesized to affect cognition or executive 
functions, and thereby school performance. The differences between the groups did not depend 
on gender, ethnicity, or living area. The causes for these results are most likely multifactorial and 
the relationships between obesity and the mediating factors, such as stigmatization and impaired 
cognitive function, are complex (Figure 12).  
Obesity-related comorbidities such as the metabolic syndrome214,215 and T2DM126,216 have been 
associated with school performance, cognition, memory, and brain structure alterations, such as 
reduction in grey matter density and volume of the hippocampus and frontal lobes. In animal 
models, insulin resistance and other obesity-related comorbidities have been shown to affect 
cognitive performance.217  
In Study IV of this thesis, the prediabetic condition IFG was not associated with lower school 
performance in the obese cohort. However, there was a non-significant tendency (p=0.06) towards 
lower risk for school completion. There might be a power issue for detecting statistical significance 
and for a fair evaluation on the impact of elevated glucose levels for school performance, larger 
studies are needed. However, the relative importance of IFG for school performance seems to be 
limited compared with the effects of the degree of obesity.  
 
 
  
Figure 12. The relationship between obesity and poor school performance is complex and multifactorial. 
 Low SES 
 Stigmatization 
 Depression 
Impaired cognition and 
executive functions 
Metabolic perturbation 
Poor School Performance Obesity 
  45 
6.10 REGISTER LINKAGE IN SWEDEN 
All residents of Sweden are assigned a personal identification number that is used by all national 
authorities. This makes it possible to extract a large amount of data that is not possible to collect 
in a clinical setting. It also makes it possible to investigate scientific hypothesis that are difficult or 
impossible to assess in other research settings. 
In the register linkage that Study III and Study IV are based on, 35 (1%) individuals from the 
BORIS registry were reported to have a non-valid personal identification number. For a quality 
register as young as BORIS, that is a fairly low number. Further, inaccuracies in the national 
registries occur. Potential pitfalls in register linkage studies include re-used or incorrect PINs 
among Swedish residents. However, this is extremely rare.218 
6.11 STATISTICAL CONSIDERATIONS 
6.11.1 The Nature of Statistics 
The statistical methods used in this thesis are quite straightforward for epidemiological research. 
However, it is important to remember that statistical methods and approaches are the way to 
describe or explain associations, and in the end, to reject a H0 hypothesis. Since statistical methods 
interpret the reality, and not vice versa, one has to remember that α or β errors might occur. 
6.11.2 Other Statistical Methods to Consider 
The basis of all parametric testing is that the sample is normally distributed, and that the association 
investigated would be the same over the distributed variable. If we suppose there is a different 
association across the distribution, neither parametric nor non-parametric tests will pick up those 
inter-variable differences. In that case, quantile regression would be more suitable since the method 
is based on the median instead of the mean, and has the potential to evaluate the association at any 
given percentile of the variable.  
6.12 LIMITATIONS 
I would like to acknowledge a number of limitations within the studies included in this thesis. Many 
have already been mentioned above. For Study I and Study II there were no cross validation of 
glucose measures between the countries. Further, no repeated glucose measurements were used. 
Another issue is that all data is reported from a large number of clinical settings and entered in 
registries. Hence, data is not from devoted research settings. Consequently, the accuracy in 
reported data might be affected. It is not possible to trace back to which method and analyzing 
kits that have been used for analysis. Further, it is impossible to assure that all samples were 
obtained during fasting conditions. However, all data collection was of clinical importance, and 
therefore in the interest of the child and the parents to obtain an accurate clinical picture. We did 
our best to test whether there were differences between small clinics and university settings with 
trained staff and laboratories or if some clinics systematically had higher or lower glucose levels 
but no such differences were found. Thus, although the accuracy is a potential error no such errors 
were identified. 
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Other general limitations involve the lack of data regarding genetics, autoantibodies for T1DM, 
family SES, parental education and health status, i.e. T2DM diagnosis. 
Regarding the longitudinal studies, no anthropometric data, i.e. BMI, at follow-up were available. 
Further, the treatment data is based on change in BMI SDS, but it was not possible to identify the 
type of treatment received (group, individual, multidisciplinary team etc).  
In Study III T2DM medication as a proxy has been used for T2DM. Hence, subjects diagnosed 
with T2DM and solely treated with behavioral modification are not identified. This group is 
reported to represent approximately 23% in this age group in Sweden. T2DM in the young obese 
population is occasionally silent, and such patients are not identified in the present study either. In 
addition, it is possible that medical treatment has been initiated for prediabetes in some individuals, 
although no national guidelines advise such practice.  
In Study IV, there are no data related to some potential confounding factors that have been 
implicated in affecting school achievement, such as parental education level and SES. However, 
the comparison subjects were matched according to the geographical area at baseline, which most 
probably reduced the risk of marked differences in socioeconomic status. The ethnic similarity 
between groups also supports the assertion that the groups were comparable. The matched 
comparison group consists of a normal population, meaning that overweight and obese subjects 
are included. Neither baseline data nor reliable epidemiological estimates of obesity prevalence are 
available for this group. Therefore, we cannot exclude an underestimation of the effects of obesity 
on both achieved educational level and risk for future use of T2DM medication. As thoroughly 
discussed above, causality of our observed results has yet to be determined.  
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7 CONCLUSION 
This thesis has shown that IFG is prevalent in both Germany and Sweden among children and 
adolescents with obesity. However, there are striking differences between these countries as 
Swedish obese children and adolescents have three times higher prevalence for unknown reasons.  
Young children with obesity in Sweden also have higher glucose levels and risk of IFG compared 
with a corresponding population in Poland.  
Provided that IFG in the obese pediatric population, as in adults, is a predictor for increased risk 
for future comorbidities, the results indicate that IFG is a prevalent threat of early development of 
obesity-related co-morbidities in young obese subjects, especially in Sweden. However, the results 
presented in this thesis seem to indicate that this is not the case. Glucose levels of ≥6.1 mmol/L 
(IFG WHO) markedly increased the risk but glucose levels between 5.6 and 6.0 mmol/L (the 
additional IFG span of ADA) were not associated with increased use of T2DM medication 
compared with obese normoglycemic children and adolescents. 
Children and adolescents treated for obesity had, despite normal glucose levels (<5.6 mmol/L), 18 
times higher risk to use T2DM medication in young adulthood than a population-based 
comparison group. Severe obesity increased the risk of T2DM medication. 
Being obese in childhood and adolescence was associated with a lower achieved educational level 
in early adulthood and, particularly for individuals with severe obesity, the differences were 
substantial. The mechanisms are unclear but most probably both socioeconomic and neurological 
factors contribute. However, IFG did not significantly increase the risk for low education in obese 
individuals. 
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